Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark.
Department of Internal Medicine-Endocrinology, Erasmus University Medical Centre, Rotterdam, Netherlands.
Adv Ther. 2023 Oct;40(10):4675-4688. doi: 10.1007/s12325-023-02627-6. Epub 2023 Aug 12.
People living with acromegaly and neuroendocrine tumours (NETs) may be treated with injectable somatostatin receptor ligands (SRLs), administered by either a caregiver or as self-injection via a proprietary or generic device. Injection device attributes that contribute to ease of use and storage, minimise preparation requirements, and reduce injection pain are associated with improved adherence and more favourable therapeutic outcomes. The aim of this study was to assess current opinion surrounding favourable SRL device attributes for people living with acromegaly and NETs as well as that of their caregivers.
Participants (healthcare professionals [HCPs] and patients/non-HCP caregivers) from 11 countries were invited to answer survey questions related to their demographic, experience, and preferences as they relate to the real-world use of injectable SRL devices. Questions were developed based on review of available literature and meetings with a Scientific Committee.
Device attributes preferred by the patient/non-HCP caregiver group (n = 211) included confidence that the correct drug amount is delivered (76%), quick administration with minimal pain/discomfort (68%), and device safety (needle-safety and low risk of contamination; 53%). Device attributes preferred by HCPs (n = 52) were quick administration with minimal pain/discomfort (69%), correct use is easy to learn, confidence in handling the device (63%), and confidence that the correct drug amount is delivered (62%).
The results identified key features of injection devices for SRL therapy which merit consideration for optimal management and underscore the importance of patient partnership in treatment decisions.
患有肢端肥大症和神经内分泌肿瘤 (NET) 的患者可能需要使用注射用生长抑素受体配体 (SRL) 进行治疗，这些药物可以由护理人员或通过专用或通用设备进行自我注射。有助于提高使用便利性和存储性、最大限度减少准备要求并降低注射疼痛的注射设备属性与提高依从性和更有利的治疗结果相关。本研究旨在评估当前关于肢端肥大症和 NET 患者及其护理人员的有利 SRL 设备属性的意见。
来自 11 个国家的参与者（医疗保健专业人员 [HCP] 和患者/非 HCP 护理人员）被邀请回答与他们在现实世界中使用注射用 SRL 设备相关的调查问题，这些问题涉及他们的人口统计学、经验和偏好。问题是基于对现有文献的回顾和与科学委员会的会议制定的。
患者/非 HCP 护理人员组（n=211）首选的设备属性包括确信能输送正确的药物剂量（76%）、能快速给药且疼痛/不适最小（68%）以及设备安全（针头安全和低污染风险；53%）。HCP 首选的设备属性包括快速给药且疼痛/不适最小（69%）、易于学习正确使用、对处理设备有信心（63%）以及确信能输送正确的药物剂量（62%）。
研究结果确定了 SRL 治疗注射设备的关键特征，这些特征值得优化管理考虑，突出了患者在治疗决策中的重要性。
